Horizon Therapeutics (HZNP) Misses Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
August 3, 2022 7:00 AM EDT
Second-Quarter 2022 Results:
-- Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million --
-- GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million --
-- TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million --
-- KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Million --
-- Cash Position of $1.89 Billion as of June 30, 2022 --
Revises Full-Year 2022 Guidance:
-- Full-Year 2022 Net Sales Guidance of $3.53 Billion to $3.60 Billion, Reflecting Revised Net Sales Expectations for TEPEZZA and Inflammation Segment... More
